Unstable angina non ST elevation myocardial infarction anticoagulant therapy

WikiDoc Resources for Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Articles
Most recent articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Most cited articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Review articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Images of Unstable angina non ST elevation myocardial infarction anticoagulant therapy Photos of Unstable angina non ST elevation myocardial infarction anticoagulant therapy Podcasts & MP3s on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Videos on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Evidence Based Medicine
Cochrane Collaboration on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Bandolier on Unstable angina non ST elevation myocardial infarction anticoagulant therapy TRIP on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Clinical Trials
Ongoing Trials on Unstable angina non ST elevation myocardial infarction anticoagulant therapy at Clinical Trials.gov Trial results on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Clinical Trials on Unstable angina non ST elevation myocardial infarction anticoagulant therapy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Unstable angina non ST elevation myocardial infarction anticoagulant therapy NICE Guidance on Unstable angina non ST elevation myocardial infarction anticoagulant therapy NHS PRODIGY Guidance FDA on Unstable angina non ST elevation myocardial infarction anticoagulant therapy CDC on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Books
Books on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
News
Unstable angina non ST elevation myocardial infarction anticoagulant therapy in the news Be alerted to news on Unstable angina non ST elevation myocardial infarction anticoagulant therapy News trends on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Commentary
Blogs on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Definitions
Definitions of Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Patient Resources / Community
Patient resources on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Discussion groups on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Patient Handouts on Unstable angina non ST elevation myocardial infarction anticoagulant therapy Directions to Hospitals Treating Unstable angina non ST elevation myocardial infarction anticoagulant therapy Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Healthcare Provider Resources
Symptoms of Unstable angina non ST elevation myocardial infarction anticoagulant therapy Causes & Risk Factors for Unstable angina non ST elevation myocardial infarction anticoagulant therapy Diagnostic studies for Unstable angina non ST elevation myocardial infarction anticoagulant therapy Treatment of Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Continuing Medical Education (CME)
CME Programs on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
International
Unstable angina non ST elevation myocardial infarction anticoagulant therapy en Espanol Unstable angina non ST elevation myocardial infarction anticoagulant therapy en Francais
Business
Unstable angina non ST elevation myocardial infarction anticoagulant therapy in the Marketplace Patents on Unstable angina non ST elevation myocardial infarction anticoagulant therapy
Experimental / Informatics
List of terms related to Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Cardiology Network
Discuss Unstable angina non ST elevation myocardial infarction anticoagulant therapy further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

ACC / AHA Guidelines (DO NOT EDIT)

“

Class I Anticoagulant therapy should be added to antiplatelet therapy in UA / NSTEMI patients as soon as possible after presentation. a. For patients in whom an invasive strategy is selected, regimens with established efficacy at a Level of Evidence: A include enoxaparin and UFH, and those with established efficacy at a Level of Evidence: B include bivalirudin and fondaparinux. b. For patients in whom a conservative strategy is selected, regimens using either enoxaparin or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have established efficacy. c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. (Level of Evidence: B) Class IIa For UA / NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin or fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 24 h. (Level of Evidence: B)

”

Sources

• The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Eleveation Myocardial Infarction